How to Get Reclast (Zoledronic Acid) in Florida

Zoledronic acid is a bisphosphonate given as a once-yearly intravenous infusion for postmenopausal osteoporosis, and it is also FDA-approved under separate dosing schedules for osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget's disease of bone. Reclast (Novartis) is the branded 5 mg/100 mL formulation; generic zoledronic acid injection is also available. This article covers the osteoporosis treatment indication only. It is prescription-only in every state, including Florida, and there is no over-the-counter or self-injectable version.

In Florida, the practical bottleneck for getting a zoledronic acid infusion is rarely finding someone licensed to prescribe it. Physicians, nurse practitioners, and physician assistants can all order it, and telehealth prescribing is legal for this drug. The bottleneck is usually the sequence that has to happen before the needle goes in: a qualifying DEXA result, current renal and calcium labs, and, for most non-Medicaid patients, a completed prior authorization. Getting those three things assembled and submitted correctly is what actually determines how fast a patient is infused, not the prescriber's credential type.

Who can prescribe zoledronic acid in Florida

Any Florida-licensed prescriber authorized to order intravenous medications can write a zoledronic acid order. That includes MDs and DOs, Advanced Practice Registered Nurses (APRNs), and Physician Assistants (PAs).

Florida's HB 607, effective July 2020, gave qualified APRNs autonomous prescribing authority, meaning a nurse practitioner who meets the statute's supervised-practice requirement can prescribe zoledronic acid without a physician co-signature. PAs prescribe under a collaborative practice agreement with a supervising physician. Because zoledronic acid is not a controlled substance, none of these prescribers face DEA-related restrictions on ordering it.

Most osteoporosis care in Florida still starts with a primary care referral to an endocrinologist or rheumatologist, though primary care clinicians increasingly manage bisphosphonate therapy directly, particularly for straightforward postmenopausal osteoporosis without complicating comorbidities.

Telehealth: what it can and cannot do

Florida's telehealth statute (F.S. § 456.47) permits a Florida-licensed prescriber to evaluate a patient by video, review DEXA and lab results submitted electronically, and transmit a zoledronic acid order to an infusion center or specialty pharmacy. Because the drug is not a controlled substance, no DEA in-person examination requirement applies.

What telehealth cannot do is deliver the drug. Zoledronic acid must be infused intravenously in a setting equipped to manage an infusion reaction, with at least 15 minutes of infusion time and a period of post-infusion observation. A telehealth visit can complete the diagnostic review and produce the order; it cannot substitute for the in-person infusion appointment.

Labs required before infusion

Zoledronic acid carries labeled warnings for hypocalcemia and renal impairment, and pre-infusion testing is a safety requirement, not an optional step.

Calcium and vitamin D. Serum calcium must be within normal range before infusion; pre-existing hypocalcemia must be corrected first. Many prescribers also check 25-hydroxyvitamin D and recommend supplementation if levels are low, since adequate vitamin D status supports calcium homeostasis after the infusion. Specific supplementation doses should come from the treating prescriber, not from this article.

Kidney function. Serum creatinine and estimated glomerular filtration rate (eGFR) are required before each infusion. The FDA label for zoledronic acid contraindicates use in patients with significant renal impairment; the exact creatinine clearance cutoff and dosing adjustments should be confirmed with the prescriber and current product labeling rather than a summary, since labeling can be revised. A basic or complete metabolic panel drawn within roughly 30 days of the planned infusion is standard practice at most infusion centers, though the acceptable window varies by facility.

DEXA scan. A dual-energy X-ray absorptiometry scan is the diagnostic basis for treatment, not a lab draw. Osteoporosis treatment guidelines from specialty societies generally support pharmacologic therapy for a qualifying T-score at the spine, femoral neck, or total hip, or for lower bone density combined with elevated FRAX-estimated fracture risk. Because guideline thresholds are periodically updated, a treating clinician should confirm current criteria rather than relying on a fixed number from any single article. Medicare and most commercial Florida plans cover DEXA screening on a periodic basis for older women, though exact intervals and age cutoffs depend on the specific plan.

The HORIZON-PFT trial, a major randomized controlled study published in the New England Journal of Medicine, demonstrated that annual zoledronic acid infusions lower the incidence of vertebral and hip fractures in postmenopausal women with osteoporosis relative to placebo, while also showing that acute-phase reactions resembling influenza commonly occur after the initial dose but generally resolve without intervention. Although specific efficacy metrics and fracture incidence figures from this trial appear in numerous summaries, reported values show minor discrepancies between sources; clinicians seeking exact numbers for patient discussions are advised to consult the original trial report directly rather than relying on secondary summaries including this one.

Separately, preclinical work continues to characterize how dose, duration, and skeletal maturity affect zoledronic acid's structural and mechanical effects on bone, including recent rodent research (Cabahug et al., 2026). That line of research is relevant to basic pharmacology and to understanding long-term skeletal effects in growing bone, but it does not establish human dosing intervals and should not be read as clinical guidance.

Where the infusion happens

Zoledronic acid requires IV administration in a clinical setting with resuscitation capability. Florida patients generally access infusion through one of three settings:

• Hospital outpatient infusion departments, run by major health systems statewide. These typically carry the highest facility fees but are broadly covered by Medicare and commercial insurance.
• Freestanding infusion centers, increasingly common in South Florida, the Tampa Bay area, and the I-4 corridor. These often bill at lower rates than hospital-based sites, which can matter for patients with high-deductible plans.
• Physician office infusion, available at some endocrinology and rheumatology practices, where the prescribing clinician can supervise the infusion directly.

Appointment lead time after prior authorization is approved varies by site and season and is not something a general article can state reliably; ask the specific facility for current scheduling availability.

Insurance and cost: what's stable and what changes

Coverage rules, deductibles, and cash prices for zoledronic acid change over time and by plan, so treat the following as a framework for asking the right questions, not as a substitute for checking your own plan documents.

Medicare Part B. Because zoledronic acid is physician-administered, it is billed under Part B rather than Part D drug coverage, and Part B generally covers it for medically necessary osteoporosis treatment. Beneficiaries owe standard Part B coinsurance after meeting the annual Part B deductible; the deductible amount is set by CMS each year and should be confirmed against the current-year Medicare.gov figure rather than assumed from a prior year.

Florida Medicaid. Coverage for zoledronic acid under Florida's Statewide Medicaid Managed Care program depends on the specific managed care plan's preferred drug list, which changes periodically. Some plans have historically limited IV bisphosphonate coverage to non-osteoporosis indications, but this is a plan-level and time-sensitive detail. A Medicaid enrollee should confirm current coverage directly with their managed care plan, and ask about the exception or prior authorization process if the initial answer is no.

Commercial insurance. Most commercial plans in Florida cover zoledronic acid with prior authorization. Typical documentation requirements include a qualifying DEXA result, evidence of intolerance to or failure of oral bisphosphonates (if the plan requires step therapy), and recent renal function labs. Approval timelines vary by insurer and are not something this article can quote reliably as a fixed range.

Manufacturer and cash-pay options. Novartis has historically offered patient assistance for branded Reclast to income-eligible uninsured or underinsured patients; program terms, income thresholds, and enrollment steps change over time and should be verified directly through Novartis rather than through a secondary source. Generic manufacturers typically do not run comparable assistance programs, but some infusion centers negotiate bundled cash pricing that includes both the drug and the administration fee; ask the specific facility for a current quote rather than relying on a published price range, since infusion drug pricing shifts.

Prior authorization: the real bottleneck

A typical PA request includes the DEXA report with qualifying result, recent labs (calcium, vitamin D, creatinine/eGFR), clinical documentation of the osteoporosis diagnosis, documentation of oral bisphosphonate intolerance or failure where the plan requires step therapy, and the prescriber's order with NPI. Incomplete submissions are a common cause of delay in bisphosphonate access generally, though the exact share of delays attributable to documentation gaps varies by study population and plan, and a specific percentage should not be treated as a fixed national or Florida-specific figure without checking the original source.

If a PA is denied, Florida patients have appeal rights. Medicare Advantage plans must decide expedited reconsiderations within a federally set turnaround time (confirm the current standard with the plan or CMS). For commercial plans regulated by the Florida Office of Insurance Regulation, external review through an independent review organization is available after internal appeals are exhausted.

Compounding pharmacies and drug shortages

Florida licenses 503A compounding pharmacies under Chapter 465 of the Florida Statutes, overseen by the Florida Board of Pharmacy. A 503A pharmacy may compound zoledronic acid for an individually identified patient under a valid patient-specific prescription. Compounding is most relevant when commercial supply is disrupted; the FDA Drug Shortage Database is the authoritative, current source for whether zoledronic acid or a specific generic manufacturer's product is in shortage, and shortage status should be checked at the time of need rather than assumed from a past report.

A Florida 503A pharmacy generally cannot ship compounded zoledronic acid across state lines unless also registered in the receiving state, but can ship within Florida to the prescriber's office or infusion center where the drug will be administered.

Transferring an existing prescription to Florida

Patients relocating to Florida, or spending part of the year there, can typically transfer an existing zoledronic acid order. Because it is not a controlled substance, this follows standard interstate pharmacy transfer practice: the receiving Florida pharmacy or infusion center contacts the originating pharmacy to verify the prescription. The prescriber does not need a Florida license to authorize the transfer, though the administering facility in Florida typically wants a Florida-licensed provider to authorize the actual infusion. Labs can be drawn at any Quest Diagnostics or Labcorp location in Florida and forwarded electronically.

Verification checklist: stable facts vs. facts you must check today

Some facts about zoledronic acid access in Florida are fixed by federal regulation or clinical evidence and change rarely. Others depend on a specific plan, pharmacy, or moment in time and can be wrong the day after they are published. Before acting on anything in this article, sort it into one of these two columns.

Stable, unlikely to change plan-by-plan or month-to-month

• Zoledronic acid is prescription-only nationwide; no OTC pathway exists.
• Florida telehealth law (F.S. § 456.47) permits remote evaluation and prescribing for non-controlled substances like zoledronic acid.
• HB 607 (2020) gives qualified Florida APRNs independent prescribing authority.
• The infusion must occur in a clinical setting with monitoring capability; a telehealth visit cannot replace it.
• Pre-infusion calcium and renal function checks are a labeled safety requirement, not a local custom.
• Zoledronic acid is billed as a Part B (not Part D) drug because it is physician-administered.

Date-sensitive, verify before relying on it

• The current Part B deductible and coinsurance amount for the current year (check Medicare.gov).
• Whether your specific Florida Medicaid managed care plan covers zoledronic acid for osteoporosis, and its exception process.
• Your specific commercial plan's prior authorization criteria and step-therapy requirements.
• Current cash price at a specific infusion center or hospital outpatient department.
• Whether zoledronic acid or a specific manufacturer's product is currently listed on the FDA shortage database.
• Current terms of any manufacturer patient assistance program, including income thresholds.
• The exact renal function cutoff and any recent label changes (check the current FDA label directly).

What's established, what's plausible, and what isn't settled

Established: Zoledronic acid 5 mg IV once yearly is FDA-approved for postmenopausal osteoporosis; the drug requires pre-infusion calcium and renal function assessment; Florida law permits telehealth evaluation and prescribing for this drug; Florida APRNs can prescribe it independently; the infusion itself requires a monitored clinical setting.

Plausible but not something this article can quantify: Typical PA approval turnaround times, typical total time from evaluation to infusion, and the share of delays caused by incomplete documentation likely vary by plan and region, but specific numbers require verification against current payer data rather than a fixed range repeated across articles.

Not established here: This article does not verify current Florida Medicaid coverage status, current cash prices, current manufacturer assistance program terms, or the current FDA-labeled renal function cutoff. Each of these is time-sensitive and should be confirmed directly with the relevant plan, pharmacy, or the current FDA label before a patient or clinician relies on it.